Evotec acquires U.S-based Just Biotherapeutics for £73.59 million

Evotec acquires U.S-based Just Biotherapeutics for £73.59 million

  • Evotech acquires the U.S. based biologics company Just Biotherapeutics for £73.59 million.
  • The German company will gain access to Just Bio's Seattle-based production facility.
  • The acquisition will improve Evotec's footprint in the United States.

In an announcement on Thursday, Evotec (ETR: EVT) said that it has acquired the U.S-based biologics company Just Biotherapeutics. The U.S. company is financially backed by the Gates Foundation.

As per the sources, Evotec is investing £73.59 million on the acquisition to boost its presence in the biologics industry. Learn more about return on assets (ROA).

The news comes only weeks after Evotec released its quarterly financial results that posted robust performance in its primary business in the first quarter. The company also released its full-year financial guidance that accounted for an economic blow from COVID-19 that has so far infected more than 178,500 people in Germany and caused over 8,000 deaths.

At £21.27 per share, the Hamburg-headquartered company is currently more than 1% down year to date in the stock market.

Evotec to gain access to Just Bio’s Seattle facility

Founded in 2014, Just Bio is a U.S company that focuses on designing, development, and production of biologics. Following the acquisition, Evotec will benefit from Just Bio’s expertise in the sector along with its workforce comprising 90 employees. Just Bio’s Seattle facility will also be accessible to Evotec.

Just Bio’s current team comprises of biologics experts from Amgen. The company is financially supported by prominent names like Bill & Melinda Gates Foundation, Lilly Asia Ventures, Merck, and ARCH Venture Partners. The U.S company aims to reduce the cost of biologics to make them more accessible for uninsured patients with budget limitations. It is committed to manufacturing enhanced therapeutic molecules at efficient production facilities.

Evotec signed a £53.15 million pact with Celgene Corporation

Evotec has signed multiple deals in recent years targeted at its local and international growth. In May 2019, the German company signed a cancer drug pact valued at £53.15 million with Celgene Corporation. The agreement was followed by its preclinical diabetes pact that it signed in August with the Danish multinational pharmaceutical company, Novo Nordisk. Evotec also announced a £57 million investment in Sanofi last summer to purchase its infectious disease unit.

Following the acquisition, Evotec aims at integrating Just Bio’s biologics based on machine-learning technologies into its drug discovery offerings. Access to Just Bio’s Seattle-based manufacturing facility for biologics will also help improve Evotec’s footprint in the United States.

Owing to the ongoing health crisis, the £3.22 billion company dropped to a year to date low of £16.81 per share in March. Evotec currently has a price to earnings ratio of 84.57.

By Wajeeh Khan
Mr. Khan specialises in Public Health by academia but is a trader by passion. Taking up two new hobbies of writing and trading in his teen years, he is now a professional trader and news writer with over 5 years of experience in various financial markets. Khan is passionate about bringing insightful articles to his readers and hopes to add value to their portfolios.

Investing is speculative. When investing your capital is at risk. This site is not intended for use in jurisdictions in which the trading or investments described are prohibited and should only be used by such persons and in such ways as are legally permitted. Your investment may not qualify for investor protection in your country or state of residence, so please conduct your own due diligence. This website is free for you to use but we may receive commission from the companies we feature on this site. Click here for more information.